非小细胞肺癌中MDR_1和MDRP基因的表达及意义

Clinical significance of MDR_1 and MDRP gene expression in patients with non small cell lung cancer

目的 探讨多药耐药基因(MDR1)和多药耐药相关蛋白基因(MDRP)在非小细胞肺癌(NSCLC)中的表达及意义。方法 采用逆转录多聚酶链反应(RTPCR),对33例NSCLC组织及相应癌旁组织中MDR1和MDRP基因表达进行检测。结果 癌组织中MDR1和MDRP阳性率(分别为69.7%和63.6%)明显高于癌旁组织(36.4%和30.3%,P<0.01);两基因的表达水平也显著高于癌旁肺组织(P<0.001,P<0.01);术前化疗者的MDR1和MDRP基因表达水平明显高于未化疗者(P<0.05)。结论 NSCLC具有内源性和获得性耐药性,检测MDR1和MDRP基因表达可指导临床化疗,并预测预后。

Objective To investigate the clinical significance of MDR 1 and MDRP gene expression in patients with non small cell lung cancer(NSCLC). Methods Using reverse transcription polymerase chain reaction (RT PCR) technique, the expression of MDR 1 and MDRP gene was determined in cancer and paracancerous tissues from 33 NSCLC patients.Results Positive expression of MDR 1 gene was 69.7% and 36.4% in lung cancer tissues and paracancerous tissues respectively, and a highly significant difference was observed between the two groups( P<0.01 ). The expression levels of MDR 1 mRNA were much higher than those in paracancerous tissues. The positivity rate of MDRP gene expression in cancer tissues was 63.6%, which was higher than 30.3% in paracancerous tissue. The gene expression levels in cancer tissues were also significantly higher than those in paracancerous tissues. The expression levels of MDR 1 and MDRP in cancer tissues of the patients receiving pre operative chemotherapy were remarkably higher than those of the patients not receiving chemotherapy (P<0.05). Conclusion NSCLC had primary and acquired multidrug resistance. It was of important significance to detect MDR 1 and MDRP gene expression in directing chemotherapy of lung carcinoma and in predicting prognosis.